Chronic Migraine
126
31
36
57
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
24 trials with published results (19%)
Research Maturity
57 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.0%
5 terminated out of 126 trials
91.9%
+5.4% vs benchmark
25%
32 trials in Phase 3/4
42%
24 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (126)
i-NEED: NEw migrainE Drugs Database
Effectiveness and Tolerability of Eptinezumab
Determining the Utility of a Behavioral Intervention in Chronic Migraine
Fire Needling Plus Filiform Needling for Chronic Migraine With Comorbid Tension-Type Headache
Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Brief Interventions in Chronic Migraine
Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Cannabis for the Prophylactic Treatment of Migraine
First Evaluation of a Craniofacial Peripheral Nerve Stimulation System in Chronic Migraine
The RECLAIM Study.
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
Mind Body Balance for Pediatric Migraine
Responding With Evidence and Access for Childhood Headaches
Non-Invasive Brain Stimulation as Add-on Treatment in Chronic Migraine With Medication Overuse
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine